Abstract
Purpose: GATA binding protein 4 (GATA4) has been implicated in the etiology of congenital malformation of the urogenital system. The present study investigated the influence of GATA4 polymorphisms on susceptibility to hypospadias. Methods: We genotyped 4 potentially functional polymorphisms (rs12458, rs12825, rs884662, and rs904018) in GATA4 in the hospital-based case-control study including 410 child patients and 520 nonmalformed individuals by the TaqMan MGB method. Risk associations were assessed using unconditional logistic regression, adjusted for potential confounding factors. Results: A significant association was found between rs12458 (3′-UTR of GATA4) and susceptibility to hypospadias (p = 0.008). Compared with rs12458 AA genotype individuals, those harboring the variant allele (rs12458 AT/TT) were correlated with significantly higher risk of hypospadias (AT/TT vs. AA: OR = 1.42, 95% CI = 1.17–2.35, p = 0.036). Furthermore, the rs12458T allele showed significantly decreased activity in a luciferase reporter assay, indicating a possible role of rs12458 variant in regulating the combination of microRNAs with the GATA4 mRNA. Conclusions: The present results indicate that the functional GATA4 rs12458 variant confers individuals’ susceptibility to hypospadias, possibly through regulating the GATA4 expression level.
References
1.
Springer
A
, van den Heijkant
M
, Baumann
S
. Worldwide prevalence of hypospadias
. J Pediatr Urol
. 2016 Jun
;12
(3
):152
–7
. .2.
Jin
L
, Ye
R
, Zheng
J
, Hong
S
, Ren
A
. Secular trends of hypospadias prevalence and factors associated with it in southeast China during 1993–2005
. Birth Defects Res A Clin Mol Teratol
. 2010 Jun
;88
(6
):458
–65
. .3.
Thai
HT
, Kalbasi
M
, Lagerstedt
K
, Frisén
L
, Kockum
I
, Nordenskjöld
A
. The valine allele of the V89L polymorphism in the 5-alpha-reductase gene confers a reduced risk for hypospadias
. J Clin Endocrinol Metab
. 2005 Dec
;90
(12
):6695
–8
. .4.
Kalfa
N
, Philibert
P
, Baskin
LS
, Sultan
C
. Hypospadias: interactions between environment and genetics
. Mol Cell Endocrinol
. 2011 Mar 30
;335
(2
):89
–95
. .5.
Molkentin
JD
. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression
. J Biol Chem
. 2000 Dec 15
;275
(50
):38949
–52
. .6.
Hu
DL
, Chen
FK
, Liu
YQ
, Sheng
YH
, Yang
R
, Kong
XQ
, GATA-4 promotes the differentiation of P19 cells into cardiac myocytes
. Int J Mol Med
. 2010 Sep
;26
(3
):365
–72
.7.
Viger
RS
, Mertineit
C
, Trasler
JM
, Nemer
M
. Transcription factor GATA-4 is expressed in a sexually dimorphic pattern during mouse gonadal development and is a potent activator of the Müllerian inhibiting substance promoter
. Development
. 1998 Jul
;125
(14
):2665
–75
. .8.
Viger
RS
, Guittot
SM
, Anttonen
M
, Wilson
DB
, Heikinheimo
M
. Role of the GATA family of transcription factors in endocrine development, function, and disease
. Mol Endocrinol
. 2008 Apr
;22
(4
):781
–98
. .9.
Lourenco
D
, Brauner
R
, Rybczynska
M
, Nihoul-Fekete
C
, McElreavey
K
, Bashamboo
A
. Loss-of-function mutation in GATA4 causes anomalies of human testicular development
. Proc Natl Acad Sci U S A
. 2011 Jan 25
;108
(4
):1597
–602
.10.
Allali
S
, Muller
JB
, Brauner
R
, Lourenço
D
, Boudjenah
R
, Karageorgou
V
, Mutation analysis of NR5A1 encoding steroidogenic factor 1 in 77 patients with 46, XY disorders of sex development (DSD) including hypospadias
. PLoS One
. 2011
;6
(10
):e24117
. .11.
Peycelon
M
, Mansour-Hendili
L
, Hyon
C
, Collot
N
, Houang
M
, Legendre
M
, Recurrent intragenic duplication within the NR5A1 gene and severe proximal hypospadias
. Sex Dev
. 2017
;11
(5–6
):293
–7
. .12.
Adamovic
T
, Thai
HT
, Liedén
A
, Nordenskjöld
A
. Association of a tagging single nucleotide polymorphism in the androgen receptor gene region with susceptibility to severe hypospadias in a Caucasian population
. Sex Dev
. 2013
;7
(4
):173
–9
. .13.
Carmichael
SL
, Witte
JS
, Ma
C
, Lammer
EJ
, Shaw
GM
. Hypospadias and variants in genes related to sex hormone biosynthesis and metabolism
. Andrology
. 2014 Jan
;2
(1
):130
–7
. .14.
Qin
XY
, Kojima
Y
, Mizuno
K
, Ueoka
K
, Massart
F
, Spinelli
C
, Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias
. J Hum Genet
. 2012 Jul
;57
(7
):434
–41
. .15.
Manjegowda
DS
, Karunakar
P
, Ramachandra
NB
. Effect of structural changes in proteins derived from GATA4 nonsynonymous single nucleotide polymorphisms in congenital heart disease
. Indian J Pharm Sci
. 2015 Nov–Dec
;77
(6
):735
–41
. .16.
Yang
XY
, Jing
XY
, Chen
Z
, Liu
YL
. Correlation between GATA4 gene polymorphism and congenital heart disease
. Int J Clin Exp Med
. 2015
;8
(9
):16733
–6
.17.
Pulignani
S
, Vecoli
C
, Sabina
S
, Foffa
I
, Ait-Ali
L
, Andreassi
MG
. 3′UTR SNPs and haplotypes in the GATA4 gene contribute to the genetic risk of congenital heart disease
. Rev Esp Cardiol
. 2016 Aug
;69
(8
):760
–5
. .18.
Lin
YH
, Xiao
Q
, Wang
JS
, Jiang
YG
. [Clinical study of congenital heart disease accompanied by hypospadias]
. Zhonghua Nan Ke Xue
. 2014 Feb
;20
(2
):169
–71
. Chinese.19.
Karakaya
AE
, Doğan
AB
, Güler
AG
. Use of a stent in distal hypospadias repaired by tubularized incised plate urethroplasty: a comparative study
. Urol Int
. 2019
;102
(3
):336
–40
. .20.
Almusafer
M
, Abduljabbar
OH
, Buchholz
N
. Stented versus non-stented snodgrass urethroplasty for distal hypospadia repair
. Urol Int
. 2020
;104
(1–2
):156
–9
. .21.
Obara
K
, Hoshii
T
, Hoshino
S
, Yamana
K
, Anraku
T
, Maruyama
R
, Free tube graft urethroplasty for repair of hypospadias
. Urol Int
. 2020
;104
(5–6
):386
–90
. .22.
Turkyilmaz
Z
, Karabulut
R
, Atan
A
, Sonmez
K
. Redo hypospadias repair: comparison of three different methods
. Urol Int
. 2020
;104
(5–6
):391
–5
. .23.
Gong
J
, Tong
Y
, Zhang
HM
, Wang
K
, Hu
T
, Shan
G
, Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis
. Hum Mutat
. 2012 Jan
;33
(1
):254
–63
. .24.
Garg
V
, Kathiriya
IS
, Barnes
R
, Schluterman
MK
, King
IN
, Butler
CA
, GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5
. Nature
. 2003 Jul 24
;424
(6947
):443
–7
. .25.
Tremblay
JJ
, Robert
NM
, Viger
RS
. Modulation of endogenous GATA-4 activity reveals its dual contribution to Müllerian inhibiting substance gene transcription in Sertoli cells
. Mol Endocrinol
. 2001 Sep
;15
(9
):1636
–50
. .26.
Tevosian
SG
, Albrecht
KH
, Crispino
JD
, Fujiwara
Y
, Eicher
EM
, Orkin
SH
. Gonadal differentiation, sex determination and normal Sry expression in mice require direct interaction between transcription partners GATA4 and FOG2
. Development
. 2002 Oct
;129
(19
):4627
–34
. .27.
Igarashi
M
, Mizuno
K
, Kon
M
, Narumi
S
, Kojima
Y
, Hayashi
Y
, GATA4 mutations are uncommon in patients with 46,XY disorders of sex development without heart anomaly
. Asian J Androl
. 2018 Nov–Dec
;20
(6
):629
–31
. .28.
Sabina
S
, Pulignani
S
, Rizzo
M
, Cresci
M
, Vecoli
C
, Foffa
I
, Germline hereditary, somatic mutations and microRNAs targeting-SNPs in congenital heart defects
. J Mol Cell Cardiol
. 2013 Jul
;60
:84
–9
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
